These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26931115)

  • 1. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
    Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
    Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
    Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Eur J Haematol; 2017 Apr; 98(4):337-347. PubMed ID: 27943422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
    Ozuah NW; Dahmoush HM; Grant FD; Lehmann LE; LaCasce AS; Billett AL; Margossian SP
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28696028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W; Zhao J; Xing Y; Wang C; Wang T
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
    Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA
    Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
    Jabbour E; Hosing C; Ayers G; Nunez R; Anderlini P; Pro B; Khouri I; Younes A; Hagemeister F; Kwak L; Fayad L
    Cancer; 2007 Jun; 109(12):2481-9. PubMed ID: 17497648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
    Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
    Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
    Adams HJA; Nievelstein RAJ; Kwee TC
    Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
    Reyal Y; Kayani I; Bloor AJC; Fox CP; Chakraverty R; Sjursen AM; Fielding AK; Ben Taylor M; Bishton MJ; Morris EC; Thomson KJ; Russell N; Mackinnon S; Peggs KS
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1234-1241. PubMed ID: 27095691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.